A generic version of the antiviral medication favipiravir, under the Favivire brand name, was recently launched by Hyderabad-based Hetero Labs, part of the Hetero group, to treat Covid-19 patients across the world.
The company has obtained approval to produce and sell its drugs from the Indian regulatory authority. DCGI has allowed the use of favipiravir for mild to moderate symptoms of coronavirus. Drug Controller General of India
At the company’s formulation facility Favivir is being manufactured. Hetero said in a statement that it was priced at Rs 59 per tablet, which has been available for prescription throughout the country at all medical, retail outlets and hospital pharmacies.
It is oral antiviral drugs with positive clinical results. Hetero added that it increases the quality of care for a large number of Covid-19 patients with mild to moderate symptoms.
Favivir is the second drug to be used in the treatment of COVID-19 developed by Hetero after Covifor (Remdesivir) has been introduced. The Japanese Fujifilm was originally developed for the treatment of influenza under the Avigan brand name.
In addition to Hetero, Cipla, Cipla, Brinton, and Jenburkt Pharmaceuticals grow or market Favipiravir in India. Favipiravir is the primary drug in this industry.
Hetero released Remdesivir under the Covifor brand in India last month, following DCGI’s approval in production and marketing.